Results 2Q25 Transf rming lives with our energy Disclaimer Certain statements and estimates in this material may represent expectations about future events or results which are subject to risks and uncertainties that may be known or unknown. There is no guarantee that events or results will occur as referred to in these expectations. These expectations are based on the present assumptions and analyses from the point of view of our management, in accordance with their experience and other factors such as the ...

Q2 2025 Highlights - Transactions reached 397,000, a 26% year-over-year growth[26] - The company achieved record revenue of $74 million, a 31% year-over-year increase[26] - The platform has expanded to include 75 carriers[26] Financial Performance - Q2 2025 revenue was $74 million, exceeding the guidance of $70 million - $71 million[55] - Adjusted EBITDA for Q2 2025 was $(29) million, aligning with the guidance of $(29) million - $(28) million[55] - Non-IFRS gross margin reached 735% for Q2 2025, compared to 720% in Q2 2024[75] Guidance - Q3 2025 transaction guidance is 419,000 - 425,000, representing a 24%-25% year-over-year growth[69] - Q3 2025 revenue is projected to be $76 million - $77 million, a 23%-25% year-over-year increase[69] - Full year 2025 revenue guidance is $295 million - $300 million, reflecting a 24%-26% year-over-year growth[69] - Full year 2025 Adjusted EBITDA is expected to be $(109) million - $(105) million[69]

Tonmya Approval and Launch - TonmyaTM is the first FDA-approved medicine for fibromyalgia in over 15 years[1,13] - Tonix is well-positioned to support the commercial launch of TonmyaTM, expected in Q4 2025[13] - Tonix ended Q2 2025 with approximately $125 million in cash and cash equivalents and raised approximately $50 million in Q3 2025 through equity sales[41] - The company anticipates its cash runway will support the launch and other operations into Q3 2026[13,41] Clinical Efficacy and Safety - Clinical trials demonstrated durable reduction in fibromyalgia pain with TonmyaTM[22] - In Trial 1, the TONMYA group showed a change from baseline of -1.9 compared to -1.5 in the placebo group, with a p-value of 0.010[28] - In Trial 3, the TONMYA group showed a change from baseline of -1.8 compared to -1.2 in the placebo group, with a p-value of less than 0.001[29] - A greater percentage of study participants taking Tonmya experienced a clinically meaningful (≥30%) improvement in their pain after three months, compared to placebo[35] - The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer[24,40,94] Market Opportunity and Commercial Strategy - Over 10 million people in the US are living with fibromyalgia[13,50] - Approximately 5% of fibromyalgia-diagnosing HCPs write approximately 70% of fibromyalgia prescriptions[62]

Financial Performance - Q2 2025 revenue reached $811 million, a 3% year-over-year increase[50, 55] - H1 2025 revenue totaled $163447 million, a 5% year-over-year increase[55, 89] - Q2 2025 Adjusted EBITDA was $21 million[50, 57] - The company repurchased 49 million shares for $233 million in Q2 2025[58, 65] - The company has approximately $85 million remaining for share repurchases as of August 15, 2025[58, 65] Market Position and Growth - Riskified reviewed approximately $145 billion in GMV in the twelve months ended June 30, 2025[16, 18] - The company estimates the global ecommerce GMV to be approximately $65 trillion in 2025 and $83 trillion in 2029[19] - Non-GAAP operating expenses as a percentage of revenue decreased from 50% to 47% year-over-year[56] Future Outlook - The company's 2025 revenue guidance is between $336 million and $346 million[59] - The company's 2025 Adjusted EBITDA guidance is between $18 million and $26 million[59] - The company expects approximately $30 million in Free Cash Flow in 2025[74]

Company Overview and Milestones - CBAK was among the first to research lithium battery applications in cars, positioning itself as a pioneer in the EV era[9] - Model 32140 cells captured 19% of the global market share, while Model 26650 captured 64% of the global market share in 2024[12] - Nanjing Branch reported a net income of RMB 2846 million with a gross margin of 2751% for the first 6 months of 2025[13] Production Capacity and Expansion - Dalian Branch's production capacity is expected to reach 33 GWh by 2025, mainly for Model 40135 cells[19] - Nanjing Branch has two production lines with a capacity of 13 GWh for lithium-ion batteries, or 06 GWh with one line for lithium-ion batteries and 048 GWh with the other line for sodium-ion batteries[24] - CBAK is planning to expand Nanjing Branch's capacity up to 20 GWh once fully constructed[24] Product Portfolio and Development - Model 40135 is about 5 times the capacity of Model 26650, 15% higher in energy density and 12% lower in cost[37] - Model 32140 sales volume captured 19% of global market share, Model 26650 for 64% of global market share[12] Financial Performance and Projections - Net revenues from battery business in the first half of 2025 totaled $7546 million, with residential energy supply & uninterruptable supplies accounting for 4704%[49] - Sales forecast for the battery segment in 2025 is projected to reach RMB 14 billion, a 4098% increase over 2024[69] - Net income for the battery segment is projected to reach RMB 100 million in 2025[70]

Financial Performance - Q2 2025 revenue reached $155.6 million[9], compared to $99.2 million[9] in Q2 2024, representing a significant increase - Adjusted EBITDA for Q2 2025 was $17.3 million[11], while Q2 2024 saw $23.5 million[11] - The company reported a net loss after tax of $147.7 million[12] for Q2 2025 - Cash and cash equivalents totaled $299.8 million[12], with crypto holdings of $169.3 million[12] Operational Highlights - SEALMINER A2 sales generated $69.5 million[12] in revenue - 21.2 EH/s of SEALMINER A2 mining rigs have been manufactured, with an additional 0.4 EH/s in final assembly as of the end of July 2025[13] - Self-mining hash rate increased from 11.5 EH/s in March 2025 to 16.5 EH/s in June 2025[15] - Hash rate of mining rigs sold increased ~17x, from 0.3 EH/s in Q1 2025 to 5.0 EH/s in Q2 2025[17] Future Growth & Capacity - The company has 1.3 GW of existing power capacity and a secured 2.7 GW pipeline[35] - Potential ASIC Revenue TAM is estimated at ~$21.25 billion[24] - Potential SEALMINER Revenue at 30% market share is estimated at ~$6.4 billion[26]

Product & Indication - PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with Recurrent Respiratory Papillomatosis (RRP)[11, 44, 55] - PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy indicated for the treatment of adults with recurrent respiratory papillomatosis[27] - The recommended dose of PAPZIMEOS is 5×10^11 particle units (PU) per injection, administered subcutaneously four times over a 12-week interval[27] Clinical Data - The pivotal study demonstrated a 51% Complete Response Rate (95% CI [34-69%])[37] - 15 out of 18 Complete Responders evaluated at 2 years demonstrated continued Complete Response[37] - PAPZIMEOS was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2[37] Commercial Strategy & Launch - The company is employing a targeted launch strategy with a field team covering >90% of ENT patient potential[47] - 93 IDNs and community hospitals account for 80% of initial target potential, with a total target universe of ~500 accounts[48] - 18 dedicated sales territories will cover >90% of ENT patient potential[47] RRP Market - Approximately 27,000 adult patients in the US have RRP[16] - IDNs and Community hospitals account for >90% of identified patient potential[46]

Transaction Overview - Formpipe is divesting its Public Sector business area to STG for up to SEK 850 million[4] - The Board intends to distribute a substantial portion of the proceeds to shareholders and reinvest the rest in Lasernet[4] - Major shareholders representing 20% of votes have entered into voting undertaking agreements[6] Financial Details - The purchase price includes SEK 775 million in cash at closing[7] - SEK 50 million will be paid through a loan note payable in 2029 with a 4.25% compounding interest rate[7] - An additional SEK 25 million will be paid if STG achieves a certain return on its investment[7] Business Performance (2024) - Formpipe Public's ARR was SEK 239 million with a 7% growth[8] - Formpipe Public's Revenue was SEK 306 million with a -5% growth[8] - Lasernet's ARR was SEK 220 million with a 21% growth[8] - Lasernet's Revenue was SEK 223 million with a 11% growth[8] - Formpipe Public's Adjusted Cash EBITDA margin was 15%[8] - Lasernet's Adjusted Cash EBITDA margin was 10%[8] Lasernet Business - Lasernet's ARR Q1'25 was SEK 214 million[11] - Lasernet serves various industries, with 68% of ARR from SaaS Support & Maintenance and 32% from other sources[11]

Financial Performance Highlights - Credicorp achieved a Return on Equity (ROE) of 20.9% in 1H25[91], and the long-term sustainable ROE target was raised from approximately 18% to approximately 19.5%[102] - Net Interest Income (NII) increased by 5.3% year-over-year (YoY) in 2Q25[83] - Fee income increased by 8.2% YoY[19], and gains on FX transactions increased by 7.9% YoY[19], while insurance underwriting results increased by 11.2% YoY[19] Key Ratios and Metrics - The Common Equity Tier 1 (CET1) ratio stood at 12.56%[14, 19], a 51 basis points (bps) increase YoY[19] - The Non-Performing Loan (NPL) ratio decreased by 102 bps YoY to 5.0%[19] - The Cost of Risk (CoR) decreased by 141 bps YoY to 1.6%[19] - The Net Interest Margin (NIM) increased by 9 bps YoY to 6.4%[19] - Low-cost deposits accounted for 57.2% of the funding base, a 274 bps increase YoY[19] Business Segment Performance - Universal Banking demonstrated strong profitability, with an ROE of 30.9% in 2Q25[37] - Yape's lending operations saw significant growth, with the number of users with loans increasing from 0.8 million in 2Q24 to 3.0 million in 2Q25[45, 47], and lending revenue share increasing from 4% to 18% over the same period[45, 47] - Mibanco Peru's ROE increased to 16.3% in 2Q25[50], driven by improved risk management and a stronger NIM[49] - Grupo Pacifico's insurance service income was S/ 847.914 million in 2Q25[59], with insurance service expenses accounting for 68.3% of the income[59] Economic Outlook and Guidance - The company expects a GDP growth of around 3%[14, 96] - The company updated its 2025 guidance, expecting a total loan portfolio growth of around 6.5%[96]

Financial Performance - Cosan's EBITDA under management reached R$ 60 billion, a decrease from R$ 73 billion in 2Q24[6] - Dividends and Interest on Capital Received amounted to R$ 06 billion, down from R$ 21 billion in 2Q24[6] - Net Debt remained stable at R$ 175 billion, consistent with 1Q25[6] - Net Income was R$ (09) billion, compared to R$ (02) billion in 2Q24[6] Operational Highlights - Rumo experienced higher transported volume, reaching 218 billion RTK, a 4% increase[12] and increased EBITDA (+6%)[12] - Compass saw growth in distributed volume (+9%)[12] - Moove experienced lower EBITDA (-12%) due to a reduction in lubricant volumes sold (-13%)[12] - Raízen experienced a reduction in EBITDA (-23%), lower crushing in ESB offset by better performance of Fuel Distribution Brazil[13] Sugarcane crushing was 25 million tons, a 21% decrease[13] - Radar's portfolio land value is R$ 168 billion, with Cosan's stake at R$ 52 billion[13] Liability Management - Cosan Corporate's Net Debt was R$ 175 billion in 2Q25[15] - The Debt Service Coverage Ratio (DSCR) was 12x LTM[6, 15] - The average cost of debt is 088%[17]